Risk of infection associated with targeted therapies for solid organ and hematological malignancies
Inhibidors de punts de control; Everolimus; Ibrutinib
| Authors: | ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2021 |
| Country: | España |
| Institution: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repository: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:11351/6653 |
| Online Access: | https://hdl.handle.net/11351/6653 http://hdl.handle.net/11351/6653 |
| Access Level: | Open access |
| Keyword: | Medicaments antineoplàstics Hematologia oncològica DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms Other subheadings::Other subheadings::/therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas Otros calificadores::Otros calificadores::/terapia |
| Summary: | Inhibidors de punts de control; Everolimus; Ibrutinib |
|---|